MRI-Guided HDR Brachytherapy for Prostate Cancer
This pilot study initiates a research program testing the early technical and clinical
performance of a novel procedure for MRI-guided high-dose-rate (HDR) prostate brachytherapy.
Testing will proceed in two cohorts of patients. In Arm 1, patients with locally recurrent
prostate cancer after radiation therapy will receive tumour-targeted salvage HDR brachytherapy.
Arm 1 of the study will be coordinated and closely integrated with a separate concurrent
study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of
this trial (UHN 05-0641-C). In arm 2, patients with locally advanced prostate cancer will
receive a boost of prostate-targeted HDR brachytherapy during external beam radiation therapy.
This technique will be prospectively evaluated in up to 100 patients. Preliminary data
acquired in this pilot study will determine the technical limits of MRI guided HDR
brachytherapy and will be critical for the judicious conduct of a subsequent phase II
This proposal is innovative in two fundamental ways: MRI-guidance, and specific tumour
targeting for HDR brachytherapy. Successful completion of this study will further
individualize local therapy, not only for the benefit of the proportion of cancer patients
for whom initial radiotherapeutic interventions have failed, but also provide valuable
technical and clinical validation that these novel image-guided (IG) approaches are
clinically feasible and could be applied more broadly in prostate cancer therapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society